Israeli pharmaceutical company Compugen, which develops genomics-based drug and diagnostic discovery tools, has sold its controlling stake in its subsidiary Keddem Bioscience. The acquisition, estimated to worth $15 million, was made by a privately owned US based investment company.
Related posts
People With Autism Experience Higher Intensity Pain
January 30, 2023
Israeli Innovation At New Bahraini Hospital
January 30, 2023
US Car Giant Signs Up For AI Vehicle Inspections
January 29, 2023
Considerate Partners Are Less Likely To Cheat
January 29, 2023
Facebook comments